The relationship between body mass index and survival in patients with renal cell carcinoma treated with nivolumab

Rákkutatás · Renal cell carcinoma

BMI was an independent prognostic factor in patients with mRCC treated with nivolumab.

Background: Immunotherapies have increased the therapeutic options for patients with metastatic renal cell carcinoma (mRCC), but the absence of prognostic indicators remains unresolved. We assessed the potential association of BMI with the overall survival (OS) of patients treated with nivolumab. Methods: We performed a retrospective study of 126 patients with histologically confirmed mRCC who began systemic ICI therapy between January 2016 and April 2022. BMI at the time of treatment start was calculated, and patients were divided into two groups: high BMI (≥25) and low BMI (<25). Therapeutic responses were determined according to RECIST v1.1. OS was defined as the time from starting ICI treatment until death or last follow‑up. Results: The cohort was 74.6% male, with a median age of 62. Median follow‑up was 18.6 months. OS was 40.6 months (95% CI: 34.2‑47.0) for patients with high BMI versus 9.4 months (95% CI: 7.0‑11.7) for patients with low BMI, with a significant association between BMI and OS (p < 0.001). Conclusions: BMI was an independent prognostic factor in patients with mRCC treated with nivolumab. Prospective and multicenter research is needed to confirm our findings.

Body mass index is a simple, readily available clinical variable that could help identify patients who are more likely to benefit from nivolumab therapy and improve individualized treatment decisions.

Bizonyítékszint: Állatkísérletes. Állatmodellben vizsgálták.

Eredeti forrás

Kapcsolódó jelek